FDA Seizes Counterfeit Ozempic: Thousands Of Fake Diabetes Drug Units Circulate, Health Warning Issued
As per media reports, the U.S. Food and Drug Administration (FDA) has taken action to seize "thousands of units" of counterfeit Ozempic, a widely-used diabetes drug known for its benefits in weight loss. The fake drugs were distributed through legitimate drug supply sources, prompting concerns about the identity, quality, and safety of the counterfeit medication.
Reportedly, Novo Nordisk, the manufacturer of Ozempic, is collaborating with the FDA to conduct testing on the seized counterfeit shots. Currently, there is limited information about the identity and safety of the fake drugs. The FDA has disclosed that five reported illnesses have been linked to the counterfeit shots, but none of them have been classified as serious.
The FDA's warning extends to the potential presence of fake 1-milligram semaglutide shots still being available for sale. The agency emphasised that not only the drug itself but also the needles, pen labels, carton, and accompanying healthcare information are counterfeit. The counterfeit products are identified by the lot number NAR0074 and serial number 430834149057.
To mitigate risks, the FDA strongly advised retail pharmacies to source authentic Ozempic only through authorised distributors. Patients are urged to obtain the medication exclusively from state-licensed pharmacies.
Concerned consumers are encouraged to report any suspected counterfeit Ozempic packages by contacting the FDA at 800-332-1088 or reaching out to their state complaint coordinator.
